文献速递乳腺技术与安全US

优化靶向MDA-MB-231乳腺癌细胞的相变造影剂

Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells.
PubMed 文献 · Ultrasound Med Biol · 2018-09-15

本研究在体外评估叶酸受体靶向相变造影剂(PCCA)与MDA-MB-231乳腺癌细胞的结合、内化及超声激活,发现十氟丁烷与十二氟戊烷50:50混合核心的内化与激活显著优于其他核心组成,且高沸点全氟碳在12秒超声暴露下激活效率高于4秒。

要点

  • 叶酸受体靶向PCCA可被MDA-MB-231乳腺癌细胞内化,经超声激活后形成细胞内微泡。
  • 十氟丁烷与十二氟戊烷50:50混合核心的细胞内化与超声激活显著优于其他核心组成。
  • 高沸点全氟碳核心在12秒超声暴露下激活效率高于4秒暴露。

核心结论

  • 叶酸受体靶向PCCA在MDA-MB-231乳腺癌细胞中的内化与超声激活受气体核心组成、孵育时间和超声暴露时间影响,50:50十氟丁烷与十二氟戊烷混合核心表现最佳。

研究设计与样本

  • 体外研究,使用叶酸受体靶向PCCA与MDA-MB-231乳腺癌细胞,评估不同气体核心组成、孵育时间(10分钟与60分钟)和超声暴露时间(4秒与12秒)对结合、内化及激活的影响,以超声激活后细胞内微泡数量为参考指标。

诊断标准与关键数值

  • 50:50十氟丁烷与十二氟戊烷混合核心的PCCA内化与超声激活显著高于50:50八氟丙烷与十氟丁烷混合核心(p < 0.0001)、十氟丁烷(p < 0.04)和十二氟戊烷(p < 0.0001)。
  • 高沸点全氟碳组成的PCCA在12秒超声暴露下激活效率高于4秒超声暴露。
  • 孵育60分钟与孵育10分钟相比,内化与激活无显著增加,超声后与超声前细胞内微泡比值分别为3.46与3.14。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Breast cancer remains a leading cause of death for women throughout the world. Recent advances in medical imaging technologies and tumor targeting agents signify vast potential for progress toward improved management of this global problem. Phase-change contrast agents (PCCAs) are dynamic imaging agents with practical applications in both the research and clinical settings. PCCAs possess characteristics that allow for cellular uptake where they can be converted from liquid-phase PCCAs to gaseous microbubbles via ultrasound energy. Previously, we reported successful internalization of folate-targeted PCCAs in MDA-MB-231 breast cancer cells followed by ultrasound-mediated activation to produce internalized microbubbles. This study examines the binding, internalization and activation of folate-receptor targeted PCCAs in MDA-MB-231 breast cancer cells as a function of gaseous core compositions, incubation time and ultrasound exposure period. In vitro results indicate that internalization and ultrasound-mediated activation of PCCAs were significantly greater using a 50:50 mixture of decafluorobutane:dodecafluoropentane compared with other core compositions: 50:50 octafluoropropane:decafluorobutane (p < 0.0001), decafluorobutane (p < 0.04) and dodecafluoropentane (p < 0.0001). Furthermore, it was found that PCCAs composed of perfluorocarbons with higher boiling points responded with greater activation efficiency when exposed to 12 s of ultrasound exposure as opposed to 4 s of ultrasound exposure. When evaluating different incubation times, it was found that incubating the PCCAs with breast cancer cells for 60 min did not produce significantly greater internalization and activation compared with incubation for 10 min; this was concluded after comparing the number of microbubbles present per cell before ultrasound versus post-ultrasound, and finding a ratio of intracellular microbubbles post-ultrasound/pre-ultrasound, 3.46 versus 3.14, respectively. The data collected in this study helps illustrate further optimization of folate-receptor targeted PCCAs for breast cancer targeting and imaging.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Hadinger KP, Marshalek JP, Sheeran PS, et al. Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells. Ultrasound Med Biol. 2018. PMID: 30228045. doi:10.1016/j.ultrasmedbio.2018.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。